Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models

Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel res...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Niranjan, Scire, Emily, Monahan, Sheena, Grojean, Meghan, Zhang, Eric, Schwarz, Margaret A., Schwarz, Roderich E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216918/
https://www.ncbi.nlm.nih.gov/pubmed/27127884
http://dx.doi.org/10.18632/oncotarget.9029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216918/
https://www.ncbi.nlm.nih.gov/pubmed/27127884
http://dx.doi.org/10.18632/oncotarget.9029

Ejemplares similares